The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes this site seems to be getting worse. So-called live data doesn't update reliably either.
Only reason I'm subscribed is to get the cheap level 2 but seriously considering cancelling it and paying out for a decent site.
Don’t worry easyp… Moneymunch is here to inform us all :-)
LSE not publishing RNS again? Then they have the nerve to invite you to subscribe?
Great progress - wonder if we’ll get a webcast/interview later?
RNS Number : 9875X
Evgen Pharma PLC
11 January 2022
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Progress with UK and US regulators for 2022 clinical trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) in relation to two clinical trials set to commence in 2022.
The first trial is a Phase I human volunteer study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of Evgen's new SFX-01 tablet formulation. In addition, the study, which will recruit volunteers randomised to active and placebo arms, will generate data on dose escalation and target pathway engagement. Evgen held a scientific advice meeting with the MHRA in December 2021 at which the draft trial protocol was discussed and the MHRA's written advice, which will reflect the discussions on the data to be submitted in support of approval of the trial, is expected in late January.
Separately, and also in accordance with time lines set out in Q1 2021, Evgen submitted an application for a pre-IND (Investigational New Drug application) meeting to the FDA in December 2021. This request has now been granted, to be effected by written responses to a meeting package that will be submitted to FDA in January. The IND will relate to a Phase Ib/II trial of SFX-01 in glioblastoma that is planned to commence in 2022 and Evgen is liaising with potential trial sites in the UK and Europe. The trial design will be adaptive to enable extension towards a registration if the data are supportive of this. In these circumstances trial sites in the US are likely to be involved.
Part of the proceeds from the 2021 placing and open offer have been applied to improve the synthesis and formulation of SFX-01 for commercial scale. This new tablet formulation will be used in all clinical trials; the production process has started and Evgen anticipates drug product will be available for commencement of the Phase I human volunteer study in Q2 this year.
Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted with the positive progress that has been made with MHRA and FDA regarding our two planned clinical trials for SFX-01, both of which we intend to commence later this year. We look forward to updating the market in due course regarding further progress with these key regulatory authorities and with regard to these two important trials."
That’s almost 50% held by the top 8shareholders
I agree that it is disappointing that the Directors haven’t invested but maybe they have options open to them?
No, not at 5.5p, big resistance at 5.71p.
As I said, I'm indifferent to the product, the bods not having any skin in the game says a lot.
What is of interest is that the free float is very illiquid, throw in the fact that you have a major shareholder holder hovering up shares at around 5p and you have all the conditions IMHO for a half decent bounce.
He'll have bought his few 100k punt, then at 5.5p or so he'll sell and start posting negative tripe again.
Like a stuck record is Kingalf.
Kingalf ,
You must have bought a few to be so confident :-)
I thought I would summarise the major shareholders in the company.
As most on here are fully aware I'm indifferent to the underlying product, what is getting me excited is that we now have a major shareholder hovering up shares at around 5p which is providing a floor. His actions are reducing the share float, which is creating an artificial opposite to a share dilution.
With the reduced number of shares it really wouldn't take much for these to hit double figures again.
J. R. Kight 30,500,000 11.1%
AXA Framlington 23,848,884 8.7%
Octopus Investments 21,875,000 8.0%
SPARK Impact 16,186,446 5.9%
Seneca Investment Managers 14,932,071 5.4%
Chelverton Asset Management 12,500,000 4.5%
RAB Capital 8,750,000 3.2%
Newlands Capital 8,314,815 3.0%
I think we're due a small bounce, but don't get too excited.
Seems like Kight still has orders to fill in using any sells that come in. Can't buy anything for the past 2 days, going straight to NT.
I have a different view, as also does Mr. Knight it would appear….
EVG actually has a very good runway of working capital cash funds in place. Indeed their strong cash (and equivalents) balance was stated as being up at 10.1 million pounds just three months ago is equivalent to 2/3rds of their market cap. You will struggle to find any other small cap pharmaceutical Companies with such a healthy balance sheet to market cap ratio.
Furthermore, EVG have potential for receipt of revenues starting within the coming year from their license agreement with Juvenescence, based on the 15th Sept 2020 RNS which stated that “It is envisaged that product launch by Juvenescence will occur within the next two years”. We could be hearing some news on this product launch fairly soon along with other EVG developments and so IMO there are plenty of positives to look forward to with EVG for patient investors going into 2022.
The guy has pumped in a £1.5 million for his holding so definitely not small change.
Still adding!
The formula one mechanics may just turn that allegro into a Ferrari :-)
Having reviewed the latest set of accounts the following caught my attention
"The Directors estimate that the cash and cash equivalents including short-term investments and cash on deposit, held by the Group together with known receivables will be sufficient to support the current level of activities into the third quarter of calendar year 2023. They have therefore prepared the financial statements on a going concern basis"
If they don't pull their finger out soon, there will be a further dilution in around 15 months.
Probably why the board don't own any shares apart from the freebies.
Still, jobs for the boys / girls is clearly evident here, it's like they've employed formula one mechanics to service an Austin Allegro.
A cynic would argue that the bods are part of an elaborate scheme to enrich themselves at the expense of shareholders. Huw's track record as a CEO is shockingly poor, just look him up at Company house.
Still some opportunities to make a small return on these, a good entry point IMHO is around 4.81p, with a potential return of around 20%.
What's happening here? Now down to below 5p. Anyone with any information on what the share price performance target is for the Management?
Why buy stock on the market When you can get granted free ones ?
They will have to get the ball rolling and the SP up if they want to get their hands on them though…
Would like to see some confidence shown by the BOD here in the form of their own cash especially Huw - time to buy some stock in the market.
Looking forward to seeing some update on milestone payments from our partner as well …
Cashburn is low so all to look forward to in 2022
Looks to be lots of Irons in the fire going into 2022 + sitting on a nice big cash balance up at 2/3rds of their 15 million market cap.
Many seem to see Knight as the only buyer but I think he is one of a few :-)
Let’s wait and see what the updates will bring …
You know who buying again this afternoon ahead of next Tuesday`s results.